AR 1006Alternative Names: AR1006
Latest Information Update: 13 Oct 2016
At a glance
- Originator AriBio
- Mechanism of Action Endoplasmin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Systemic lupus erythematosus
Most Recent Events
- 01 Jun 2016 Early research in Systemic lupus erythematosus in South Korea (unspecified route)